Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
16.81
-1.05 (-5.85%)
Sep 21, 2026, 1:01 PM EDT - Market open
Summit Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Summit Therapeutics stock has a consensus rating of "Buy" and an average price target of $28.81. The average 1-year stock price forecast is 71.44% higher than the current stock price, while the lowest is $10.85 (-35.44%) and the highest is $41.15 (+144.87%).
Price Target: $28.81 (+71.44%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 9 | 9 | 9 | 9 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 5 | 5 | 5 | 7 | 6 |
| Sell | 1 | 2 | 2 | 2 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $18 | Hold | Maintains | $18 | +7.11% | Sep 21, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $41 | Buy | Maintains | $41 | +143.98% | Sep 14, 2026 |
| Citi | Citi | Buy Maintains $40 | Buy | Maintains | $40 | +138.02% | Sep 14, 2026 |
| UBS | UBS | Buy Maintains $33 | Buy | Maintains | $33 | +96.37% | Sep 14, 2026 |
| Jefferies | Jefferies | Buy Upgrades $15 → $25 | Buy | Upgrades | $15 → $25 | +48.77% | Sep 9, 2026 |
Financial Forecast
Revenue This Year
3.91M
Revenue Next Year
55.82M
from 3.91M
Increased by 1,327.04%
EPS This Year
-1.15
from -1.43
EPS Next Year
-1.18
from -1.15
EPS and Forward PE are based on non-GAAP adjusted numbers.